Patents Examined by D Margaret M Seaman
  • Patent number: 10053428
    Abstract: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: August 21, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Hahn, Markus Follmann, Eva-Maria Becker, Johannes-Peter Stasch, Joerg Keldenich, Martina Delbeck, Hanna Tinel, Frank Wunder, Joachim Mittendorf, Ildiko Terebesi, Dieter Lang, René Martin, Walter Hübsch
  • Patent number: 10040765
    Abstract: The invention relates to new and improved processes for the preparation of Indacaterol and pharmaceutically acceptable salts thereof as well as intermediates for the preparation of Indacaterol. The new process avoids the use of the epoxide compound known in the art and the impurities associated therewith and results in a higher yield.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 7, 2018
    Assignee: Crystal Pharma S.A.U.
    Inventors: Antonio Lorente Bonde-Larsen, Yolanda Fernández Sainz, Jesús Iglesias Retuerto, Javier Gallo Nieto
  • Patent number: 10039759
    Abstract: The invention relates to new quinoline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 7, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Patrick René Angibaud, Steven John Woodhead, Gordon Saxty
  • Patent number: 10035788
    Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 31, 2018
    Assignee: WYETH LLC
    Inventors: Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
  • Patent number: 10035763
    Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 31, 2018
    Assignee: GTX, INC.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
  • Patent number: 10022455
    Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 17, 2018
    Assignee: Translate Bio, Inc.
    Inventors: Frank Derosa, Michael Heartlein
  • Patent number: 10023557
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: July 17, 2018
    Assignee: LIFESCI PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Patent number: 10023538
    Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: July 17, 2018
    Assignees: The United States of America as represented by the Department of Veterans Affairs, Oregon Health and Science University
    Inventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
  • Patent number: 10023552
    Abstract: [Problem] To provide a process suitable for mass-producing of iso-liquiritigenin. [Solution] A process for preparing iso-liquiritigenin, which comprises steps of coupling a 4-alkoxycinnamic acid represented by formula (I) with a 1,3-alkoxybenzene represented by formula (II) through the Friedel-Crafts reaction (A) to synthesize a tri-alkoxy-iso-liquiritigenin represented by formula (III), to crystallize out the reaction product, and eliminating the protecting groups therefrom to obtain iso-liquiritigenin, represented by formula (IV). The iso-liquiritigenin (IV), is administered as a precursor for liquiritigenin represented by formula (V) to the body, thereby obtaining in vivo a pharmacological effect of the (?) isomer of liquiritigenin.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: July 17, 2018
    Inventor: Haruo Higo
  • Patent number: 10016408
    Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: July 10, 2018
    Assignee: EMORY UNIVERSITY
    Inventors: Lawrence J. Wilson, John Wiseman, Dennis C. Liotta, Michael G. Natchus
  • Patent number: 10017471
    Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 10, 2018
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
  • Patent number: 10010541
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chaitan Khosla, Thomas DiRaimondo, Cornelius Kloeck
  • Patent number: 10005747
    Abstract: The present invention provides a process for the hydrogenation of the levulinic acid to ?-valerolactone in a single step with a single Pt supported on hydrotalcite catalyst. The process provides conversion of ?-valerolactone over Pt supported hydrotalcite catalyst at room temperature (25° C.). The process provides a levulinic acid conversion of 34-100% with 20-50 bar hydrogen pressure to give ?-valerolactone selectivity up to 99%.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: June 26, 2018
    Assignee: Council of Scientific and Industrial Research
    Inventors: Bal Rajaram, Pendem Chandrashekar, Bordoloi Ankur, Konathala Laxmi Narayan Sivakumar, Manoj Kumar, Saran Sandeep
  • Patent number: 10005766
    Abstract: A compound represented by formula (4) is produced by a step A of reacting a compound represented by formula (2): wherein R1 represents an ethyl group or the like, R represents a halogen atom or the like, n represents 0, 1, 2, or 3, and M represents potassium or the like, with thionyl chloride to obtain a compound represented by formula (1): a step B of reacting the compound represented by formula (1) with a compound represented by formula (5): wherein A1 represents a nitrogen atom or ?CH—, R5 represents a trifluoromethyl group or the like, and m represents 1 or 2, to produce a compound represented by formula (3): or an acid salt thereof; and a step C of reacting the compound represented by formula (3) or an acid salt thereof in the presence of acid at 100° C. to 180° C.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: June 26, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Takashi Miyamoto, Daisuke Sasayama
  • Patent number: 10005734
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R8 are described herein.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: June 26, 2018
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Patent number: 9975889
    Abstract: Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols A, X, Y, L1, L2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: May 22, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stefan Hillebrand, Pierre Cristau, Sebastian Hoffmann, Joachim Kluth, Pierre Wasnaire, Tomoki Tsuchiya, Juergen Benting, Ulrike Wachendorff-Neumann, Thomas Seitz
  • Patent number: 9975853
    Abstract: The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the Hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: May 22, 2018
    Inventors: Manik Chatterjee, Andreas Hartung, Ulrike Holzgrabe, Elisabeth Mueller, Ulrich Peinz, Christoph Sotriffer, David Zilian
  • Patent number: 9969691
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 15, 2018
    Assignee: LUPIN LIMITED
    Inventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Patent number: 9969693
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 15, 2018
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Patent number: 9969714
    Abstract: The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: May 15, 2018
    Assignee: Eli Lilly and Company
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Katherine Marie Partridge, Jeremy Schulenburg York